STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation
Paula Granado‐Martínez, Sara García-Ortega, Elena González‐Sánchez, Kimberley McGrail, Rafael Selgas, Judit Grueso, R. Sánchez Gil, Neia Naldaiz‐Gastesi, Ana Carolina Rhodes, Javier Hernández‐Losa, Berta Ferrer-Rosell, Françesc Canals, Josep Villanueva, Olga Méndez, Sergio Espinosa-Gil, José M. Lizcano, Eva Muñoz‐Couselo, Vicenç García-Patos, Juan A. Recio
Abstract
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. Here, we investigated the contribution of four missense LKB1 somatic mutations in tumor biology. Three out of the four mutants lost their tumor suppressor capabilities and showed deficient kinase activity. The remaining mutant retained the enzymatic activity of wild type LKB1, but induced increased cell motility. Mechanistically, LKB1 mutants resulted in differential gene expression of genes encoding vesicle trafficking regulating molecules, adhesion molecules and cytokines. The differentially regulated genes correlated with protein networks identified through comparative secretome analysis. Notably, three mutant isoforms promoted tumor growth, and one induced inflammation-like features together with dysregulated levels of cytokines. These findings uncover oncogenic roles of LKB1 somatic mutations, and will aid in further understanding their contributions to cancer development and progression.